ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 07, 2021 16:00 JST
Source:
TetraQ
Agilex Biolabs acquires leading biolab TetraQ for APAC Expansion Plans
Adelaide / Brisbane, West Australia, Apr 07, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the acquisition of leading biolab TetraQ, based at the University of Queensland. Agilex Biolabs CEO Jason Valentine said they were very pleased with the purchase of the high-calibre bioanalytics company.
"TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services," he said. "The TetraQ purchase is part of our regional expansion plans. Agilex Biolabs is already the largest and most technologically advanced biolab in Australia, and the TetraQ addition to the business will further expand support for biotech clients running trials in Australia."
"We are also looking forward to introducing our clients to the well-established TetraQ toxicology capabilities for their discovery and pre-clinical work in Australia, which can also attract the 43.5% tax rebate. The clinical trials bioanalytics sector is one of the fastest-growing services globally with Australia and APAC a preferred location for conducting trials - especially since the COVID-19 pandemic."
TetraQ Director Dr Peter Tapley said he was very pleased that TetraQ was now an Agilex Biolabs company. "They are the leader in the sector with 24 years of experience, and offer our clients a significantly expanded range of services and technologies," he said.
"Agilex Biolabs is known globally for its comprehensive services, specialist scientists, and the very latest technology. So this is the ideal next step for TetraQ and its staff and clients. I am pleased to be working alongside Agilex Biolabs' CEO Jason Valentine as we expand our offering and leverage the synergies that make our two companies leaders in the sector."
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarker and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)
Agilex Biolabs has 75 dedicated laboratory staff, and supports clinical research for biotech clients from US, Europe and APAC. The company recently launched a GALEXI client portal, and has taken delivery of two more Sciex API 6500+ LC-MS/MS systems. Key certifications include OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and an ISO 17025 global accreditation.
About Agilex Biolabs -- www.agilexbiolabs.com.
Agilex Biolabs, Australia's leading bioanalytical laboratory, has more than 20 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world's most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia. We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising LC-MS/MS and Immunoassay platforms.
About TetraQ -- www.tetraq.com.au.
TetraQ is a Brisbane-based provider of bioanalytical and rodent toxicology and pharmacokinetics services for new drug and vaccine products. Our facility has NATA recognition for compliance with the OECD Principles of Good Laboratory Practice (GLP). Our bioanalytical facility is located at the Royal Brisbane and Women's Hospital, and our in-life studies are run in a custom unit at the St Lucia campus of The University of Queensland. These two arms of TetraQ offer coordinated support for clients bringing pharmaceutical products to market.
TetraQ's bioanalytical facility determines small molecule and protein concentrations in matrices including plasma, serum, urine and tissue homogenates. We can develop and validate methods to support pharmacokinetic (PK) sample analysis for both pre-clinical and clinical studies. We also offer pharmacodynamic (PD) analysis of biomarkers based on commercial ELISA kits or Meso Scale Discovery multiplex technology.
Agilex Biolabs media contact:
Kate Newton
Media@AgilexBiolabs.com
Source: TetraQ
Sectors: BioTech, Healthcare & Pharm
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
IDC MarketScape names Hitachi Energy a Leader in Asset Performance Management for Worldwide Utilities
Feb 18, 2026 10:51 JST
Fujitsu named to FORTUNE Magazine's list of 'World's Most Admired Companie's for eighth year running
Feb 18, 2026 10:41 JST
Fujitsu automates entire software development lifecycle with new AI-Driven Software Development Platform
Feb 17, 2026 12:21 JST
Snow master Evans leads 1-2-3-4 finish for TGR-WRT
Feb 16, 2026 15:24 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 16, 2026 14:03 JST
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026
Feb 13, 2026 22:50 JST
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026
Feb 13, 2026 22:33 JST
Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts
Feb 13, 2026 22:24 JST
MHI Successfully Demonstrates Production of Liquid Synthetic Fuels through an integrated Process Utilizing SOEC Co-Electrolysis and FT Synthesis
Feb 13, 2026 22:03 JST
JCB Sponsors the NHK Symphony Orchestra Singapore Concert 2026 - Celebrating 60 Years of Singapore-Japan Relations
Feb 13, 2026 14:00 JST
Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST
Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST
Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
More Latest Release >>
Related Release
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
May 12 2022 15:00 JST
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
October 19 2021 15:00 JST
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research
September 24 2021 09:00 JST
Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia
August 26 2021 13:00 JST
Premier of South Australia Launches $1.5m Vaccine and Immunobiology State-of-the art Laboratory for APAC Clinical Trials
July 14 2021 17:00 JST
Agilex Biolabs and Gyros Protein Technologies Partner for BioAnalysis Zone Webinar on Singlicate Analysis
May 31 2021 13:00 JST
Agilex Biolabs Partners with Endpoints News on Deconvoluting Inflammation and Immunology for Clinical Trials
May 21 2021 11:00 JST
Agilex Biolabs' Toxicology Tapped for SARS-CoV-2 Vaccine Research
May 17 2021 21:00 JST
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results
April 30 2021 13:00 JST
Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials
April 29 2021 04:00 JST
More Press release >>